csl behring€¦ · factors and pathophysiology responsible for the development of various lung...

TABLE OF CONTENTSAcknowledgements Educational Grants ................................................................................................3 Exhibitors ..............................................................................................................4Course Information ....................................................................................................5 & 6 Course Description, Objectives, Target Audience, Needs Assessment, Accreditation Statement, Cultural and Linguistic Competency Statement Faculty List ........................................................................................................................7Faculty Disclosures ............................................................................................................8Program ..............................................................................................................................9Faculty Bios UC SAN DIEGO PROGRAM DIRECTORS Kamyar Afshar, DO........................................................................................................10 Gordon Yung, MD ..........................................................................................................11

UC SAN DIEGO PARTICIPATING FACULTY Saima Aslam, MD ..........................................................................................................12 Douglas Conrad, MD ....................................................................................................13 Eugene Golts, MD..........................................................................................................14 Seth Kligerman, MD ......................................................................................................15 Demos Papamatheakis, MD ..........................................................................................16

The 1st Annual

ADVANCED LUNG DISEASE SYMPOSIUMSaturday, June 1, 2019 Estancia La Jolla Hotel La Jolla, California

2

ACKNOWLEDGEMENTSWe would like to offer a very special thank you to the following

companies for their educational grants.

Bayer HealthCare Pharmaceuticals

CSL Behring

The 1st Annual


3

ACKNOWLEDGEMENTSWe would like to acknowledge the following companies and

organizations for exhibiting at this conference.

ActelionBayer HealthCare Pharmaceuticals

Boehringer Ingelheim

Genentech, Inc.

Grifols

Hill-Rom

United Therapeutics

UC San Diego Health

The 1st Annual


4

COURSE DESCRIPTIONThis program is intended to provide a comprehensive overview of the most recent information on the riskfactors and pathophysiology responsible for the development of various lung disease that can lead toadvanced stages and the need for lung transplantation. In addition, topics will focus on gene therapy aswell as bacteriophage therapies to help with infectious complications.

The course content has been designed to provide state-of-the-art, clinically relevant topics to enhance theclinician’s practice in the treatment of advanced lung disease patients.

TARGET AUDIENCEThis course is designed for pulmonary, critical care and internal medicine physicians, nurses, respiratorytherapy, pharmacy, physical therapy and all other allied healthcare professionals.

SPECIFIC OBJECTIVESAt the conclusion of this activity, participants should be able to:1) Summarize the factors placing patients at risk for the development of various interstitial lung diseases and the corresponding therapies.2) Describe the therapeutic approach to patients with genetic conditions such as alpha 1-antitrypsin deficiency and cystic fibrosis.3) Discuss the surgical procedure available for lung transplantation and the immediate and long-term outcome benefits from this operation.4) Describe the potential role of bacteriophage therapy for selected patient groups with resistant bacterial infections.5) Describe various therapies for pulmonary hypertension, including the role of pulmonary artery balloon dilation in select patients with chronic thromboembolic pulmonary hypertension.

NEEDS ASSESMENTThough many of the challenges in the recognition, assessment and care of patients with advanced lung dis-ease have been satisfactorily met, others remain, while new ones have arisen. With advancement of theimaging technologies of computerized tomography, the opportunity to detect various interstitial lung dis-eases has been advanced, and may avert the need for a lung biopsy. Over the past quarter century, therecognition and proper treatment of various lung diseases have lagged behind patient needs. Many patientsare also underdiagnosed with genetic conditions based on a selection bias. This may in turn delay thera-peutic options for patients with alpha 1 antitrypsin deficiency or cystic fibrosis.

The global expansion of specialized centers for the evaluation and treatment of patients with chronicthromboembolic disease has resulted in the ability to care for a greater number of patients afflicted withthis previously fatal disorder.

However, the selection criteria for patients who might be considered candidates forThromboendarterectomy….the therapy which offers the greatest chance for a cure…. varies considerably.And though the availability of pulmonary hypertensive medical therapy has expanded over the past decade,the patients with CTEPH who would be best treated with these medications remains incompletely defined.

The 1st Annual


5

ACCREDITATION STATEMENTThe University of California, San Diego School of Medicine is accredited by the Accreditation Council forContinuing Medical Education to provide continuing medical education for physicians.

The University of California, San Diego School of Medicine designates this live activity for a maximumof 5.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with theextent of their participation in the activity.

For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category1 Credit(s)™ issued by organizations accredited by the ACCME. For the purpose of relicensure, theCalifornia Board of Registered Nursing accepts AMA PRA Category 1 Credit(s)™ (report up to 5.25 hoursof credit and list “CME Category 1” as the provider number).

CULTURAL AND LINGUISTIC COMPETENCYThis activity is in compliance with California Assembly Bill 1195 which requires continuing medicaleducation activities with patient care components to include curriculum in the subjects of cultural and lin-guistic competency. Cultural competency is defined as a set of integrated attitudes, knowledge, and skillsthat enables health care professionals or organizations to care effectively for patients from diverse cul-tures, groups, and communities. Linguistic competency is defined as the ability of a physician or surgeonto provide patients who do not speak English or who have limited ability to speak English, direct com-munication in the patient’s primary language. Cultural and linguistic competency was incorporated intothe planning of this activity. Additional resources on cultural and linguistic competency and informationabout AB1195 can be found on the UCSD CME website at http://cme.ucsd.edu.

6

The 1st Annual


Saima Aslam, MDAssistant Professor of Medicine Infectious Disease Director, Solid Organ Transplant Infectious Disease Service

Douglas Conrad, MDPulmonologistProfessor of Medicine Director, Adult Cystic Fibrosis ProgramDirector, Pulmonary Function Laboratory, VA Medical Center

Eugene Golts, MDCardiothoracic Surgeon Associate Professor of SurgeryDirector, Lung Transplantation

Seth Kligerman ,MDRadiologistAssociate Professor of RadiologyChief, Cardiothoracic Imaging

Demos Papamatheakis, MDPulmonologist Associate Clinical Professor of Medicine

UC SAN DIEGO PROGRAM DIRECTORS

UC SAN DIEGO PARTICIPATING FACULTY

Kamyar Afshar, DOAssociate Professor of Medicine Director, Advanced Lung Disease Program

Gordon Yung, MDProfessor of MedicineDirector, Lung Transplant Program

7

The 1st Annual


!

!

It is the policy of the University of California, San Diego School of Medicine to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individual’s control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose are disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.

Name Name of Commercial Interest Nature of Relevant Relationship

Employee, Grants/Research Support recipient, Board Member, Advisor or Review Panel member, Consultant, Independent Contractor, Stock Shareholder (excluding

mutual funds), Speakers’ Bureau, Honorarium recipient, Royalty recipient, Holder of Intellectual Property Rights,

or Other Kamyar Afshar, MD Grifols

GSK Speakers Bureau Spouse is an employee

Demosthenes Papamatheakis, MD Actelion LLC Speakers Bureau/Honoraria

The following have no relevant financial relationships to disclose:

Saima Aslam, MD, Douglas Conrad, MD, Eugene Golts, MD, Seth Kligerman, MD, Gordon Yung, MD The CME staff, meeting planners, and CME committee reviewers do not have any relevant financial relationships to disclose. This educational activity may contain discussion of unlabeled and/or investigational uses of agents that are not approved by the FDA. Please consult the prescribing information for each product. The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, San Diego.

DISCLOSURES

8

The 1st Annual


7:15-8:15am Registration/Coffee

MORNING SESSION8:15-8:30am Introductions, Welcome and Program Overview

Kamyar Afshar, DO

8:30-9:00am Pulmonary Arterial Hypertension: Approach and Therapy Demos Papamatheakis, MD9:00-9:05am Q&A

9:05-9:35am CTEPH: State of the Art Treatment Demos Papamatheakis, MD9:35-9:40am Q&A

9:40-10:10am Cystic Fibrosis and Gene Modifiers: Diagnostic Implications Douglas Conrad, MD10:10-10:15am Q&A10:15-10:35am Coffee Break/Visit Exhibits

10:35-11:05am Early Clinical Experience with Bacteriophage Therapy Saima Aslam, MD11:05-11:10am Q&A

11:10-11:40am Radiologic Evaluation of Interstitial Lung Disease Seth Kligerman, MD11:40-11:45am Q&A11:45-1:00pm Lunch

AFTERNOON SESSION

1:00-1:30pm Differentiating Sarcoidosis from IPF Kamyar Afshar, DO1:30-1:35pm Q&A

1:35-2:05pm Appropriate Selection: Which Patient Should You Refer for Lung Transplantation? Gordon Yung, MD 2:05-2:10pm Q&A

2:10-2:40pm Perioperative Mechanical Extracorporeal Support for Lung Transplant Patients Eugene Golts, MD2:40-2:45pm Q&A

2:45-3:15pm Alpha 1 Antitrypsin Deficiency Practice at Lung Transplant Centers Kamyar Afshar, DO3:15-3:20pm Q&A

3:20-3:30pm Concluding Remarks Drs. Kamyar Afshar and Gordon Yung

3:30pm Adjourn Meeting

PROGRAM

9

Kamyar Afshar, DOAssociate Professor of Medicine

Director, Advanced Lung Disease ProgramUC San Diego

La Jolla, California

Kamyar Afshar, DO, is a board-certified pulmonary and critical care physician whospecializes in lung transplantation and advanced lung disease. He has extensiveexpertise in treating alpha 1-antitrypsin deficiency, cystic fibrosis, COPD and inter-stitial lung diseases.

Prior to joining UC San Health, Dr. Afshar was assistant professor and director ofadvanced lung disease at the USC Keck School of Medicine and served as medicaldirector of the Pediatric Lung Transplant Program at Children’s Hospital LosAngeles.

Dr. Afshar completed his fellowship and residency at USC Medical Center andearned his medical degree from Midwestern University’s Arizona College ofOsteopathic Medicine. He is board-certified in internal medicine, pulmonary dis-ease and critical care medicine.

Dr. Afshar is a member of various professional societies and conducts clinicalresearch in multiple areas. He is widely published and has contributed to textbooksin pulmonary medicine. He also serves on several publication review boards.

Clinical Expertise- Medical management of advanced-stage pulmonary issues- Post lung transplant medical management- Alpha 1-antitryspin deficiency/COPD- Cystic fibrosis and bronchiectasis- Systemic sarcoidosis- Comprehensive evaluations of interstitial lung diseases

The 1st Annual


10

Gordon Yung, MDProfessor of Medicine

Director, Lung Transplant ProgramUC San Diego


Gordon Yung, MD, is a board-certified pulmonologist and medical director of lungtransplantation. He specializes in advanced lung disease and lung transplantation.

His clinical and research interests include evaluation and management of lungtransplantation and end-stage COPD/emphysema, evaluation and management ofpulmonary hypertension, and new treatments for pulmonary fi brosis.

As a professor at UC San Diego School of Medicine, Dr. Yung trains medical stu-dents, residents and fellows.

He completed a fellowship at UC San Diego School of Medicine and his residencyat New York University Hospital. He earned his medical degree from the Universityof Hong Kong. He is board certifi ed in critical care medicine and pulmonary disease.

In addition to English, Dr. Yung speaks Cantonese.

Clinical Expertise - Lung Transplantation - Interstitial Lung Disease - Pulmonary Hypertension - COPDUC

The 1st Annual


11

Saima Aslam, MDAssistant Professor of Medicine

Infectious Disease Director, Solid Organ Transplant Infectious Disease Service

UC San DiegoLa Jolla, California

Dr Aslam is an Associate Professor and Medical Director for the Solid OrganTransplant Infectious Diseases service at the University of California, San Diego.She completed her medical degree with honors from the Aga Khan University inKarachi, Pakistan and subsequently completed her Internal Medicine andInfectious Diseases training at Baylor College of Medicine, Houston, Texas. DrAslam's research interests are focused on biofilm based infections, in particularmechanical circulatory support devices, as well as multi-drug resistant organismsin the setting of solid organ transplantation.

The 1st Annual


12

Douglas Conrad, MDPulmonologist

Professor of Medicine Director, Adult Cystic Fibrosis Program

Director, Pulmonary Function Laboratory, VA Medical CenterUC San Diego


Dr Douglas Conrad is a Professor of Medicine in the the Division of Pulmonary,Critical Care and Sleep Medicine. A graduate of Case Western Reserve UniversityMedical School, he received Internal Medicine training at the University ofMinnesota and finished his Pulmonary/Critical Care Fellowship at the University ofCalifornia San Francisco. He founded the UCSD Adult Cystic Fibrosis Program in1996. His research interests include the mechanisms regulating airway inflamma-tion, airway infections as well as the CF airway microbiome.

The 1st Annual


13

Eugene Golts, MDCardiothoracic Surgeon

Associate Professor of SurgeryDirector, Lung Transplantation


Eugene Golts, MD, is a board-certified general and cardiothoracic surgeon whoperforms the full scope of cardiothoracic surgery and thoracic organ transplanta-tion. Dr. Golts is surgical director of the Lung Transplant Program at UC San DiegoHealth, the only lung transplantation program in the greater San Diego area.

Dr. Golts completed his fellowship in cardiovascular and thoracic surgery and hisresidency in general surgery at UC San Diego School of Medicine. He received hismedical degree from Loyola University Chicago’s Stritch School of Medicine.

Dr. Golts was a nurse anesthetist in his native Ukraine and worked as an ICU nursein Northern California after immigrating to the United States in 1992. He appreci-ates his nursing background for giving him a unique perspective on the patient andfamily experience in hospital settings.

He serves on the editorial board of the Journal of Thoracic and CardiovascularAnesthesiology and is co-author of many research papers and surgical textbookchapters. Dr. Golts is a member of the Society of Thoracic Surgeons.

Research & Clinical Expertise- Aortic surgery and endovascular surgery- Minimally invasive aortic valve surgery- Coronary revascularization- Heart and lung transplant- Ventricular assist device (VAD) implantation- Treatment of atrial arrhythmias

The 1st Annual


14

Seth Kligerman ,MDRadiologist

Associate Professor of RadiologyChief, Cardiothoracic Imaging


Seth J. Kligerman, MD, is a board-certified diagnostic radiologist and an associate profes-sor in the Department of Radiology at UC San Diego School of Medicine.

Dr. Kligerman is the division chief of Cardiothoracic Imaging at UC San Diego Health andhas clinical expertise in interpreting imaging studies of patients with a variety of thoracic(lung) and cardiac diseases. He was awarded an advanced proficiency in cardiac computedtomography (CT) imaging by the American College of Radiology.

His research examines the pathogenesis of fibrotic lung disease, low-dose CT imaging,advanced CT reconstruction techniques and infiltrative cardiomyopathies. He has alsoinvestigated the relationship between disease status as inferred from imaging studies anddisease status based on pathology reports (examination of tissue under the microscope).

Dr. Kligerman is a lecturer in both cardiac and thoracic imaging at the American Institute ofRadiologic pathology and serves on multiple research committees related to cardiothoracicimaging. He is published widely in his field and is a frequent invited lecturer nationally andinternationally.

Prior to joining UC San Diego Health in 2017, Dr. Kligerman was an associate professor inthe Department of Diagnostic Radiology and Nuclear Medicine at the University ofMaryland School of Medicine.

Dr. Kligerman completed fellowship training in thoracic imaging at Massachusetts GeneralHospital, Harvard Medical School. He completed residency training in radiology at theUniversity of Colorado School of Medicine. He earned his medical degree from ChicagoMedical School. Dr. Kligerman is board-certified in diagnostic radiology.

He is a member of many professional organizations, including the American College ofRadiology, the Radiological Society of North America, and the Society of ThoracicRadiology.

The 1st Annual


15

Demos Papamatheakis, MDPulmonologist

Associate Clinical Professor of MedicineUC San Diego


Dr. Papamatheakis is an Associate Clinical Professor for the Pulmonary, CriticalCare and Sleep Division at UC San Diego (UCSD). He grew up in Greece, wherehe completed his medical school training, and then moved to Canada where he didclinical research. After completing his residency in internal medicine in Michigan,he did a Pulmonary and Critical Care fellowship at Loma Linda University inCalifornia. He has been a member of the Pulmonary Vascular Group since joiningUCSD in 2011, focusing on Pulmonary Arterial Hypertension (PAH) and ChronicThromboembolic Pulmonary Hypertension (CTEPH). His clinical interests, in addi-tion to pulmonary vascular disease, include critical care medicine and general pul-monary clinic with the pulmonary medicine trainees. His research interests focuson clinical pulmonary vascular medicine and he is an investigator on multiple clin-ical trials for PAH and CTEPH. He has previously published in the fields of glauco-ma, pulmonary vascular contractility and long-term hypoxia and has also authoredmultiple reviews and chapters in the field of pulmonary vascular medicine. Finally,he is very active in medical student education, directing the Pulmonary System IIblock for the 2nd year class at UCSD School of Medicine, and does both formal(lectures) and informal (educational rounds) teaching for the residents and fellows.

The 1st Annual


16

csl behring€¦ · factors and pathophysiology responsible for the development of various lung...

Documents